Axon Enterprise, Inc. (NASDAQ:AXON - Get Free Report) Director Caitlin Elizabeth Kalinowski sold 450 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total value of $271,831.50. Following the completion of the sale, the director now directly owns 6,929 shares of the company's stock, valued at $4,185,601.03. This represents a 6.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Axon Enterprise Trading Up 0.4 %
NASDAQ:AXON traded up $2.17 during trading hours on Thursday, reaching $596.49. 516,530 shares of the company were exchanged, compared to its average volume of 611,868. The firm has a market cap of $45.49 billion, a price-to-earnings ratio of 154.13, a PEG ratio of 14.19 and a beta of 1.01. The stock has a 50 day simple moving average of $590.55 and a 200 day simple moving average of $437.04. Axon Enterprise, Inc. has a 52-week low of $241.72 and a 52-week high of $698.67. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in AXON. Quent Capital LLC increased its stake in Axon Enterprise by 1,875.0% during the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 75 shares during the last quarter. Prestige Wealth Management Group LLC grew its holdings in shares of Axon Enterprise by 115.8% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 44 shares during the period. Brooklyn Investment Group acquired a new stake in Axon Enterprise during the 3rd quarter worth approximately $41,000. Planning Capital Management Corp raised its holdings in Axon Enterprise by 83.3% in the third quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company's stock valued at $48,000 after buying an additional 55 shares during the period. Finally, Friedenthal Financial acquired a new position in Axon Enterprise during the third quarter valued at approximately $51,000. 79.08% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities research analysts have recently commented on the company. Needham & Company LLC boosted their price target on Axon Enterprise from $525.00 to $600.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. The Goldman Sachs Group boosted their price target on Axon Enterprise from $385.00 to $441.00 and gave the stock a "buy" rating in a report on Wednesday, October 23rd. Northland Securities lifted their price objective on Axon Enterprise from $365.00 to $550.00 and gave the stock an "outperform" rating in a research report on Monday, November 11th. JMP Securities upped their target price on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a "market outperform" rating in a report on Thursday, October 31st. Finally, Robert W. Baird lifted their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an "outperform" rating in a report on Friday, December 6th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $488.67.
Check Out Our Latest Analysis on Axon Enterprise
Axon Enterprise Company Profile
(
Get Free Report)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Read More
Before you consider Axon Enterprise, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axon Enterprise wasn't on the list.
While Axon Enterprise currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.